NCT02253550View on ClinicalTrials.gov

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Chronic Hepatitis C
Interventions
DRUG

Simeprevir

Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.

DRUG

Sofosbuvir

Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.

Trial Locations (1)

90036

Peter J. Ruane, MD, Inc., Los Angeles

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Peter J. Ruane, M.D.

OTHER

NCT02253550 - Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter